Last Updated: 08/01/2026
Development of a novel vaccine against Plasmodium vivax malaria using adenovirus and Modified Vaccinia Ankara (MVA) as recombinant vaccines
Objectives
The aim of this project is to develop a vaccine against the pre-erythrocytic stages of P. vivax parasites using a leading strategy that has proved successful for P. falciparum vaccine development: the use of recombinant chimpanzee adenoviral vector ChAd63 and MVA to induce strong T-cell responses, as well as the use of virus-like particles (VLPs) to stimulate antibody responses.
Nuffield Department of Medicine (NDM), University of Oxford, United Kingdom
Inspired by the Gates malaria forum in 2007, the goal to eradicate malaria has come back to the global health agenda 40 years after the initial commitment by the WHO to eradicate this disease and thus, efforts to prevent and cure the most prevalent and neglected form of malaria caused by P. vivax will increase as a result of this renewed interest. P. vivax is the most widely distributed human malaria, representing the major cause of this disease outside Africa. It is considered that this parasite threatens nearly 40% of the human population.
Stimulating immune responses against Plasmodium vivax by applying a leading vaccination strategy consisting on using clinically relevant adenoviral and MVA viral vectors will help prevent infection, disease and relapse through the elimination of pre-erythrocytic or liver-stage parasite forms.
Feb 2012 — Jan 2017
$1.53M
Related Resources
